OncorMed offers genetic testing for inherited cancers:
This article was originally published in Clinica
Executive Summary
OncorMed has launched a test for mutations in the recently discovered BRCA2 breast and ovarian cancer gene. The company which is based in Gaithersburg, Maryland, is providing the new service in combination with its existing BRCA1 test. Approximately 185,000 patients will be diagnosed with breast cancer this year in the US. Between 5 and 10% of breast cancer is hereditary, with BRCA1 mutations accounting for about 45% and BRCA2 mutations accounting for about 35% of these cases.
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.